Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02087059
What this trial is testing

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Who this might be right for
Primary Myelofibrosis (MF)
Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Study completedNCT04884191
What this trial is testing

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost- Essential Thrombocythemia Myelofibrosis
CTI BioPharma 165
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT01981850
What this trial is testing

RO7490677 In Participants With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Hoffmann-La Roche 125
Early research (Phase 1)Study completedNCT03895112
What this trial is testing

MPN-RC 118 AVID200 in Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
John Mascarenhas 21
Large-scale testing (Phase 3)Study completedNCT00934544
What this trial is testing

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 219
Testing effectiveness (Phase 2)WithdrawnNCT04054245
What this trial is testing

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Ended earlyNCT01790295
What this trial is testing

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost Polycythemia Vera MyelofibrosisPost Essential Thrombocythemia Myelofibrosis
John Mascarenhas 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07447817
What this trial is testing

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Who this might be right for
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
John Mascarenhas 26
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Large-scale testing (Phase 3)Ended earlyNCT02055781
What this trial is testing

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
CTI BioPharma 311
Early research (Phase 1)Looking for participantsNCT06218628
What this trial is testing

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Fox Chase Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT02718300
What this trial is testing

INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 74
Not applicableLooking for participantsNCT06073847
What this trial is testing

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Bristol-Myers Squibb 137
Early research (Phase 1)Active Not RecruitingNCT04279847
What this trial is testing

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Who this might be right for
MyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more
Incyte Corporation 140
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Study completedNCT01445769
What this trial is testing

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Incyte Corporation 45
Large-scale testing (Phase 3)Ended earlyNCT04551053
What this trial is testing

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 177
Next Page